Zai Lab (ZLAB) EBIT Margin (2019 - 2026)

Zai Lab (ZLAB) posted EBIT Margin of 69.66% for Q1 2026, down 28.06% sequentially from 54.39% in Q4 2025, and down 1678.0% YoY from 4.41% in Q1 2025.

Zai Lab (ZLAB) EBIT Margin (2019 - 2026) Analysis & Trends

Zai Lab has reported EBIT Margin for 8 years, with the latest figure at 69.66% in Q1 2026.

Quarterly EBIT Margin fell 1678.0% year-over-year to 69.66% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 53.5% (up 1059.0% YoY) and the FY2025 annual result came in at 49.86%, up 2085.0% from the prior year.
EBIT Margin fell to 69.66% in Q1 2026 per ZLAB's latest filing, from 54.39% in the prior quarter.
Over five years, EBIT Margin peaked at 42.05% in Q3 2025 and troughed at 223.47% in Q3 2022.
A 5-year average of 109.3% and a median of 80.68% in 2024 frame the typical range for EBIT Margin.
The sharpest annual moves came in 2022 and 2023: EBIT Margin jumped 95893 bps in 2022, then sank 3292 bps in 2023.
Over 5 years, EBIT Margin stood at 155.42% in 2022, then retreated by 21 bps to 188.34% in 2023, then soared by 67 bps to 62.25% in 2024, then climbed by 13 bps to 54.39% in 2025, then slipped by 28 bps to 69.66% in 2026.
According to Business Quant data, EBIT Margin over the past three periods registered 69.66%, 54.39%, and 42.05% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	30.15%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	31.68%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	19.06%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-105.20%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	19.75%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	17.93%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-0.36%
10	Zai Lab	2.91 Bn	2.20 Bn	58.15 Mn	-71.95%

Download Data